TW202345799A - Ｔｙｋ２抑制劑及其用途 - Google Patents

Ｔｙｋ２抑制劑及其用途 Download PDF

Info

Publication number
TW202345799A
TW202345799A TW112111352A TW112111352A TW202345799A TW 202345799 A TW202345799 A TW 202345799A TW 112111352 A TW112111352 A TW 112111352A TW 112111352 A TW112111352 A TW 112111352A TW 202345799 A TW202345799 A TW 202345799A
Authority
TW
Taiwan
Prior art keywords
compound
patient
psoriasis
hours
weeks
Prior art date
Application number
TW112111352A
Other languages
English (en)
Chinese (zh)
Inventor
艾倫 約翰 柯里斯
維納亞 賀沙圭哈萊
巴斯卡 斯里瓦斯塔瓦
Original Assignee
美商林伯士拉克許米公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商林伯士拉克許米公司 filed Critical 美商林伯士拉克許米公司
Publication of TW202345799A publication Critical patent/TW202345799A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112111352A 2022-03-25 2023-03-25 Ｔｙｋ２抑制劑及其用途 TW202345799A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263269943P 2022-03-25 2022-03-25
US63/269,943 2022-03-25
US202263371033P 2022-08-10 2022-08-10
US63/371,033 2022-08-10
US202363490664P 2023-03-16 2023-03-16
US63/490,664 2023-03-16

Publications (1)

Publication Number Publication Date
TW202345799A true TW202345799A (zh) 2023-12-01

Family

ID=88102041

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112111352A TW202345799A (zh) 2022-03-25 2023-03-25 Ｔｙｋ２抑制劑及其用途

Country Status (10)

Country Link
US (1) US20250213572A1 (enExample)
EP (1) EP4499104A4 (enExample)
JP (1) JP2025510813A (enExample)
KR (1) KR20240165963A (enExample)
AU (1) AU2023237900A1 (enExample)
CA (1) CA3246157A1 (enExample)
CL (1) CL2024002824A1 (enExample)
MX (1) MX2024011693A (enExample)
TW (1) TW202345799A (enExample)
WO (1) WO2023183901A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263861A2 (en) * 2023-06-23 2024-12-26 Dana-Farber Cancer Institute, Inc. Methods of treating chronic lymphocytic leukemia
EP4780462A1 (en) * 2023-09-21 2026-07-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN122341608A (zh) * 2023-11-24 2026-07-03 苏州科睿思制药有限公司 Zasocitinib的晶型及其制备方法和用途
WO2026032374A1 (zh) * 2024-08-07 2026-02-12 正大天晴药业集团股份有限公司 含联环的化合物用于治疗银屑病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors

Also Published As

Publication number Publication date
MX2024011693A (es) 2024-11-08
US20250213572A1 (en) 2025-07-03
CA3246157A1 (en) 2023-09-28
EP4499104A1 (en) 2025-02-05
AU2023237900A1 (en) 2024-10-10
JP2025510813A (ja) 2025-04-15
EP4499104A4 (en) 2025-09-03
KR20240165963A (ko) 2024-11-25
CL2024002824A1 (es) 2025-02-14
WO2023183901A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7724241B2 (ja) Ｉｒａｋ分解剤の結晶形態
US12551564B2 (en) IRAK degraders and uses thereof
US20250213572A1 (en) Tyk2 inhibitors and uses thereof
US20260049095A1 (en) Deuterated stat3 degraders and uses thereof
US20260078125A1 (en) Tyk2 inhibitors and uses thereof
TWI794885B (zh) 全身紅斑性狼瘡之治療
EP3526222A1 (en) Tyk2 inhibitors and uses thereof
KR20250083546A (ko) Irak4 분해자의 염 형태
US20230322754A1 (en) Irak inhibitors and uses thereof
JP2024506858A (ja) Ｇｐｒ８４アンタゴニストおよびその使用
US20260092078A1 (en) Stat6 degraders and uses thereof
US20250215002A1 (en) Solid forms of tyk2 inhibitors and methods of use
AU2023317742A1 (en) Substituted pyridone gpr84 antagonists and uses thereof
JP2025510844A (ja) Ｔｙｋ２阻害剤の合成及びその中間体
US20250221997A1 (en) Tyk2 inhibitor formulations and methods of making the same
JP2025527250A (ja) ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
JP2025503491A (ja) Ｏｘｅｒ１アンタゴニスト及びその使用
CN118973583A (zh) Tyk2抑制剂及其用途
TW202529769A (zh) Ｔｙｋ２抑制劑及其用途
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus